Skip to main content
. 2025 Jul 11;15(16):7956–7972. doi: 10.7150/thno.113303

Figure 2.

Figure 2

O-GlcNAcylation enhances YAP stability and nuclear translocation to promote YAP-driven VSMC proliferation/migration. A) YAP mRNA expression in PMSMCs with or without PDGF-BB (n = 3). Data shown as mean ± SEM, ns, no significance (one-way ANOVA with Tukey's posttest). B) Immunoblotting and quantitative analysis (relative to Actin) of YAP in PMSMCs treated with cycloheximide (20 μM) and PDGF-BB for indicated times. C) Immunoblot analysis of O-GlcNAcylated YAP in PMASMCs treated with PDGF-BB using an O-GlcNAc-specific antibody (n = 3). D) Schematic representation of the glucose metabolic flow pathway. E) LC/MS analysis heat map of various metabolites in the intracellular glucose metabolic pathway after PDGF-BB treatment (n = 4). (F-K) PMSMCs treated with PDGF-BB (10 ng/mL) and DMSO (solvent), OSMI-1 (15 μM), or TMG (10 μM) for 24 h. F) Immunoblot analysis of YAP in cells treated with cycloheximide (20 μM) for indicated time. G) Immunoblot analysis of YAP in cells treated with MG132 (10 μM) for indicated time. H) SEM images of cell morphology and immunofluorescence images of YAP (green) and DAPI (blue) (n = 3). Scale bars, 50 μm (morphology) and 10 μm (immunofluorescence). I) mRNA expression of the YAP downstream target gene representative of CYR61 (n = 3). **p < 0.01, ****p < 0.001 (one-way ANOVA with Tukey's posttest). J) Transwell Migration Assay image and the quantitative number of migrating cells indicated the migration ability of the cells (n = 3), and K) the cell counts indicated the proliferation of the cells (n = 3). **p < 0.01 (one-way ANOVA with Tukey's posttest).